Sort   by:  
 Page size 
MetabolomicsGut Microbiota Regulates Serum Metabolites in Mice with Nonalcoholic Fatty Liver Disease via Gut Metabolites: Mechanisms Involving Branched-Chain Amino Acids and Unsaturated Fatty Acids

In recent years, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease globally. Studies indicate that the gut-liver axis plays an important role in the occurrence and development of this disease. Our previous studies showed that the gut microbiota and gut meta...

2025-07-02 | MTBLS12668 | MetaboLights
MetabolomicsStudy on the Hepatoprotection of Schisandra chinensis Caulis Ploysaccharides in nonalcoholic fatty liver disease in rats based on metabolomics

The aim of this study was to investigate the hepatoprotection of Schisandra chinensis Caulis polysaccharides (SCP) in the nonalcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD) in rats. A total of 30 Wistar rats were randomly divided into control group (CON), model group...

2021-08-24 | MTBLS3194 | MetaboLights
MetabolomicsMulti-omic profiles of human nonalcoholic fatty liver disease tissue highlight heterogenic phenotypes
Non-alcoholic fatty liver disease (NAFLD) is a consequence of sedentary life style and high fat diets with an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms in, e.g. APOC3, ...
2015-12-07 | MTBLS174 | MetaboLights
MetabolomicsNonalcoholic fatty liver disease (NAFLD) Studies
Not available
ORGANISM(S): Homo sapiens 
ST000665 | MetabolomicsWorkbench
MetabolomicsGenome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leading to chronic liver disease and type 2 diabetes. Here we chart liver metabolic activity and functionality in NAFLD by integrating global transcriptomic data, from human liver biopsies, and metabolic flux data, measured across the ...
2016-12-15 | MTBLS298 | MetaboLights
MetabolomicsEstablishment of a Short-term Mouse Model of Non-alcoholic Fatty Liver Disease with Non-invasive Monitoring

Non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), are major chronic liver diseases associated with hepatocellular carcinoma. This study aimed to establish a short-term modified Western diet (mWD)-induced NAFLD model in middle-aged mice and ...

2026-05-31 | MTBLS13096 | MetaboLights
MetabolomicsPlatycodin D attenuates alcohol-associated fatty liver disease by suppressing TLR4–NF-κB and activating PPAR signaling

Alcohol-associated fatty liver disease (AFLD) is driven by ethanol-induced metabolic dysregulation and hepatic inflammation, with gut dysbiosis and endotoxin-triggered innate immune activation implicated in disease progression. Platycodin D (PD), a triterpenoid saponin from Platycodon grandifloru...

2026-01-12 | MTBLS13658 | MetaboLights
MetabolomicsAlistipes putredinis Alleviates Metabolic-Associated Fatty Liver Disease via the Acetate-GPR43 Axis by Suppressing Neutrophil ROS Generation

Background & Aims:

Intestinal dysbiosis contributes to the pathogenesis of metabolic-associated fatty liver disease (MAFLD), though precise bacterial targets and mechanisms remain incompletely elucidated. This study investigated whether the depletion of Alistipes putredinis (AP) in adol...

2026-01-16 | MTBLS13699 | MetaboLights
MetabolomicsMetabolic Characteristics of Schisantherin B in Mice with Metabolic-Associated Fatty Liver Disease

Objectives: To observe the pharmacokinetic differences of schisantherin B (STB) in the blood and liver of normal and metabolic-associated fatty liver disease (MAFLD) mice, as well as the changes in CYP450 enzymes in MAFLD mice. Methods: A MAFLD model was established in C57 mice fed with a high-fa...

2025-10-29 | MTBLS13232 | MetaboLights
MetabolomicsDT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates

Nonalcoholic steatohepatitis (NASH) prevalence is rising with no pharmacotherapy approved. A major hurdle in NASH drug development is the poor translatability of preclinical studies to safe/effective clinical outcomes, and recent failures highlight a need to identify new targetable pathways. Dysr...

2023-04-13 | MTBLS5005 | MetaboLights
Sort   by:  
 Page size